Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Roshini Claire Anthony, 6 days ago

Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.

 

Nelipepimut-S may prevent recurrence in triple-negative breast cancer

22 Jun 2020

The concurrent use of nelipepimut-S (NPS), a vaccine designed to stimulate CD8 T cells, in trastuzumab-treated patients with breast cancer and low HER2 expression is safe and does not contribute to excess toxicity, as well as prolongs disease-free survival (DFS) specifically in those with triple-negative breast cancer (TNBC), as shown in the results of a phase II trial.

A total of 275 patients received trastuzumab for 1 year and were randomized to treatment with NPS (n=136) or placebo (n=139) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). There were no clinicopathologic differences between groups.

The patients had HER2 1+ or 2+ (for IHC 2+ tumours, ISH nonamplified) invasive breast cancer; were node positive or oestrogen and progesterone receptor negative (TNBC); and were disease-free following completion of surgery, chemotherapy, and radiation.

Compared with placebo, treatment with NPS was safe with no additional overall or cardiac toxicity.

During a median follow-up of 25.7 months, estimated DFS did not significantly differ between NPS and control groups (hazard ratio [HR], 0.62, 95 percent confidence interval [CI], 0.31–1.25; p=0.18). However, planned exploratory analysis showed that NPS yielded a marked increase in DFS in the group of TNBC patients (HR, 0.26, 95 percent CI, 0.08–0.81; p=0.01).

Based on the present data, NPS will be further evaluated in a phase III trial involving TNBC patients with residual disease after neoadjuvant chemotherapy, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Roshini Claire Anthony, 6 days ago

Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.